NYSE - Nasdaq Real Time Price USD

Enzo Biochem, Inc. (ENZ)

Compare
1.1500 0.0000 (0.00%)
At close: October 31 at 4:00 PM EDT
1.1700 +0.02 (+1.74%)
After hours: October 31 at 7:55 PM EDT
Loading Chart for ENZ
DELL
  • Previous Close 1.1500
  • Open 1.1400
  • Bid --
  • Ask --
  • Day's Range 1.1200 - 1.1765
  • 52 Week Range 0.9900 - 1.5000
  • Volume 66,868
  • Avg. Volume 67,268
  • Market Cap (intraday) 59.176M
  • Beta (5Y Monthly) 0.73
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1900
  • Earnings Date Dec 13, 2024 - Dec 17, 2024
  • Forward Dividend & Yield 0.40 (34.78%)
  • Ex-Dividend Date Nov 15, 2024
  • 1y Target Est --

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

www.enzo.com

125

Full Time Employees

July 31

Fiscal Year Ends

Recent News: ENZ

View More

Performance Overview: ENZ

Trailing total returns as of 10/31/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ENZ
17.27%
S&P 500
19.62%

1-Year Return

ENZ
18.44%
S&P 500
36.93%

3-Year Return

ENZ
66.57%
S&P 500
23.89%

5-Year Return

ENZ
64.51%
S&P 500
87.26%

Compare To: ENZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ENZ

View More

Valuation Measures

Annual
As of 10/31/2024
  • Market Cap

    59.18M

  • Enterprise Value

    10.31M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.83

  • Price/Book (mrq)

    1.05

  • Enterprise Value/Revenue

    0.32

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -81.73%

  • Return on Assets (ttm)

    -7.44%

  • Return on Equity (ttm)

    -14.59%

  • Revenue (ttm)

    31.91M

  • Net Income Avi to Common (ttm)

    -9.82M

  • Diluted EPS (ttm)

    -0.1900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    52.37M

  • Total Debt/Equity (mrq)

    6.25%

  • Levered Free Cash Flow (ttm)

    -18.95M

Research Analysis: ENZ

View More

Revenue vs. Earnings

Revenue 8.02M
Earnings -3.02M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Company Insights: ENZ

People Also Watch